This is an amended filing · View original →
SAM CHUN DANG PHARM CO. LTD Q1 report amended to add designation as an unfaithful disclosure company
SAI summary · Not investment advice
SAM CHUN DANG PHARM CO. LTD amended its Q1 report to add its designation as an unfaithful disclosure company. Q1 consolidated operating profit was KRW 5.4 billion.
Operating profit · 3 months
KRW 5.4 billion
Prior-year period KRW 687.7 million
Key facts
- Revenue (3 months)
- KRW 64.9 billion
- Net income (3 months)
- KRW 6.9 billion
- Period
- Q1 (2026.01.01 ~ 2026.03.31)
- Basis
- Consolidated
- Revenue (prior-year 3 months)
- KRW 50.6 billion
- Operating profit (prior-year 3 months)
- KRW 687.7 million
- Net income (prior-year 3 months)
- KRW 1.3 billion
Commentary
AI commentary · Not investment advice
What happened
SAM CHUN DANG PHARM amended its Q1 report (the report on January to March results and company status). It added a fact that was left out of the original filing. The KOSDAQ Market Division of the Korea Exchange designated the company as an unfaithful disclosure company, meaning it broke disclosure rules. The penalty was 5.0 points. The company had released Canadian market results for SCD411, an Eylea biosimilar, as a press release without a formal disclosure. The exchange treated this as a failure to make a fair disclosure on earnings.
In the company's terms
Q1 consolidated revenue was KRW 64.9 billion, compared with KRW 50.6 billion a year earlier. Operating profit was KRW 5.4 billion, up from KRW 687.7 million a year earlier. Net income was KRW 6.9 billion.
What changes for shareholders
The company said the designation came with no fine and no demand to replace its disclosure officer. Its cumulative penalty over the past year is 5.0 points. It said it is strengthening checks on whether press releases require a disclosure before they go out.
Earlier Periodic Report filings from this company
| Filed | Title | Key figure · Note |
|---|---|---|
| 26.11.132026.11.13 | Periodic Report | KRW 3.5 billion |
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist